Publications

5674 Results

S1314 Correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation

Authors
E Plimack;C Tangen;M Plets;R Kokate;J Xiu;C Nabhan;E Ross;E Grundy;W Choi;C Dinney;I-L Lee;MS Lucia;T Flaig;D McConkey
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 4581), poster 72; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S1314

Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for Previously Treated Stage IV or recurrent Squamous Cell Lung Cancer patients from the Phase III SWOG LungMAP S1400I trial

Authors
E Parra;D Duose;J Zhang;M Redman;R Lazcano;M Piubelli;C Laberiana Fernandez;B Zhang;J Lindsay;R Moravec;K Kannan;R Luthra;G Al-Atrash;R Herbst;I Wistuba;S Gettinger;L Bazhenova;J Lee;J Zhang;C Haymaker
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9046), poster 34; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab

Authors
E Gonzalez-Kozlova;H-H Huang;M Redman;R Herbst;S Gettinger;L Bazhenova;H Xie;M Patel;K Nie;J Harris;C Argueta;K Kelly;E Cerami;R Biswas;S Van Nostrand;R Moravic;D Del Valle;S Kim-Schulze;S Gnjatic
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9044), poster 32; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

Neoadjuvant PD-1 Blockade in Patients with Resectable Desmoplastic Melanoma (SWOG 1512)

Authors
K Kendra;J Moon;Z Eroglu;S Hu-Lieskovan;W Carson;D Wada;J Plaza;G In;A Ikeguchi;J Hyngstrom;A Brohl;B Chmielowski;N Khushalani;J Markowitz;M Monroe;K Grossmann;V Sondak;E Sharon;M Wu;A Ribas
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9502), abstract 9502; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
S1512

Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481)

Authors
M Trivedi;J Unger;D Hershman;A Darke;D Hertz;T Brannagan;SJ Smith;W Irvin;A Hathaway;A Vander Woude;V Gudena;NL Henry;M Fisch
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 12024), poster 270; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1714

A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic Stk11 Genomic Alterations (SWOG S1900C, LUNG-MAP SUB-STUDY, NCT#04173507)

Authors
F Skoulidis;M Redman;J Suga;T Al Baghdadi;J Villano;S Goldberg;L Villaruz;K Minichiello;D Gandara;R Herbst;K Kelly
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9060), poster 48; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1900C

Overall survival from a phase II randomized study of ramucirumab pluspembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy—Lung-MAP non-matched sub-studyS1800A

Authors
K Reckamp;M Redman;K Dragnev;L Villaruz;B Faller;T Al Baghdadi;S Hines;L Qian;K Minichiello;D Gandara;K Kelly;R Herbst
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9004), Abstract #9004; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1800A

A059102: A Randomized Phase II US Intergroup Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Authors
N Mehta-Shah;N Bartlett;S Barta;J Amengual;S Horwitz;B Kahl;J Friedberg;T Dockter;S Geyer;J Leonard
Journal / Conference
ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session
Year
2022
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A051902

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC)

Authors
H Arai;Y Yang;J Millstein;Y Denda;F-S Ou;F Innocenti;H Takeda;A Doi;Y Horie;K Umemoto;N Izawa;J Wang;F Battaglin;N Kawanishi;P Jayachandran;S Soni;W Zhang;A Venook;Y Sunakawa;H-J Lenz
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3586), poster 380; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Gene Expression of Vitamin D (VitD) Pathway Markers and Survival in Patients (Pts) with Metastatic Colorectal Cancer (mCRC): Findings from CALGB/SWOG 80405 (Alliance)

Authors
C Kohn;F-S Ou;C Ma;N Larson;T Zemla;C Yuan;D Niedzwiecki;B Hollis;A Nixon;H-J Lenz;CD Blanke;R Goldberg;R Mayer;A Venook;E O'Reilly;J Meyerhardt;K Ng
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3553), poster 347; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405